Alkermes Stock Surges on Positive ADHD Drug Proof-of-Concept Data

Key Facts

1Alkermes stock jumped following the first proof-of-concept for its orexin-modulating drug in adults with ADHD.

In a move reflecting the expansion of neurological treatment applications, Alkermes announced positive clinical results for its candidate drug. According to reports, the company's stock jumped following the first successful proof-of-concept for its orexin-modulating drug in adults with ADHD. This development follows the company's successful application of its development strategy from narcolepsy treatments to the broader ADHD market.

Drugs impacting orexin, a brain chemical involved in wakefulness, have historically been utilized for insomnia and narcolepsy, but Alkermes' data represents a significant expansion into ADHD indications. Per market data, ALKS closed at $43.39 on September 18, 2026, having reached a day high of $46.53, highlighting investor optimism regarding the company's entry into this major therapeutic segment.

Traders are currently watching for the stock to maintain levels above the $43.27 support established on September 18, 2026. In the absence of major upcoming biotech-specific catalysts in the economic calendar, further clinical trial updates from the company will remain the primary driver for price action.